Literature DB >> 7175192

The effect of different antibody affinities on ELISA absorbance and titer.

O P Lehtonen, E Eerola.   

Abstract

Twenty-one rabbit serum samples were assayed for IgG antibodies against 3-iodo-5-nitrophenyl-epsilon-amino-n-caproic acid (NIP-cap) by equilibrium dialysis and enzyme-linked immunosorbent assay (ELISA). The results of ELISA, expressed either as absorbances or titers, did not correlate to antibody concentration or average affinity measured by the equilibrium dialysis. Affinity distributions of the antibodies within each sample were determined by equilibrium dialysis in 30 antigen concentrations. Thus, it was possible to study the correlation of ELISA results with separate ranges of antibody affinities. ELISA absorbances measured at a low sample dilution (1:80) correlated with high affinity antibodies (affinity greater than 8 X 10(-6) M-1). Use of high antigen density increased this correlation. End-point titers obtained at a low cut-off absorbance level tended to correlate to a larger range of affinities (affinity greater than 6 X 10(4) M-1). ELISA measures antibodies of different affinities depending on how the results are expressed. This can be utilized in qualitative characterization of the measured antibodies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7175192     DOI: 10.1016/0022-1759(82)90064-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  Antibody response to Achromobacter xylosoxidans during HIV infection is associated with lower CD4 levels and increased lymphocyte activation.

Authors:  Erick T Tatro; Intan Purnajo; Douglas D Richman; Davey M Smith; Sara Gianella
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

2.  Evaluation of serologic assays for diagnosis of whooping cough.

Authors:  G Granström; B Wretlind; C R Salenstedt; M Granström
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

3.  Nature and reactivity of staphylococcal enterotoxin A monoclonal antibodies.

Authors:  C Edwin; S R Tatini; S K Maheswaran
Journal:  Appl Environ Microbiol       Date:  1986-12       Impact factor: 4.792

Review 4.  Progress in enzyme immunoassays: production of reagents, experimental design, and interpretation.

Authors:  E Kurstak
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  Definition of Brucella A and M epitopes by monoclonal typing reagents and synthetic oligosaccharides.

Authors:  D R Bundle; J W Cherwonogrodzky; M A Gidney; P J Meikle; M B Perry; T Peters
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

6.  Avidity of antibodies against released proteins of Yersinia spp: comparison of patients with or without reactive arthritis.

Authors:  R Lahesmaa-Rantala; J Heesemann; O P Lehtonen; K Granfors; A Toivanen
Journal:  Ann Rheum Dis       Date:  1989-12       Impact factor: 19.103

7.  Mycobacterial aetiology of Crohn's disease: serologic study using common mycobacterial antigens and a species-specific glycolipid antigen from Mycobacterium paratuberculosis.

Authors:  S N Cho; P J Brennan; H H Yoshimura; B I Korelitz; D Y Graham
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

8.  Induction of immune and adjuvant immunoglobulin G responses in mice by Brucella lipopolysaccharide.

Authors:  E Moreno; R S Kurtz; D T Berman
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

9.  Amount and avidity of salivary and serum antibodies against Streptococcus mutans in two groups of human subjects with different dental caries susceptibility.

Authors:  O P Lehtonen; E M Gråhn; T H Ståhlberg; L A Laitinen
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

10.  Nonspecific induction of immunoglobulin M antibodies to periodontal disease-associated microorganisms after polyclonal human B-lymphocyte activation by Fusobacterium nucleatum.

Authors:  D F Mangan; T Won; D E Lopatin
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.